Anti-Albuminuric Effects of the Angiotensin AT1 Receptor Blocker Telmisartan in Hypertensive Patients

Abstract

We evaluated the anti-hypertensive and anti-albuminuric effect of the angiotensin receptor blocker telmisartan alone and in combination with torasemide and amlodipine. Patients were hypertensive, both diabetics and non-diabetics with persistent microalbuminuria. Our primary endpoint was a change in microalbuminuria levels, while the secondary endpoints were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine levels, and glomerular filtration rate.After the 16-week treatment period, the patients significantly reduced microalbuminuria levels (76.4 ± 52.4 μg/min; p < 0.001), SBP (16.4 ± 8.7 mmHg; p < 0.001) and DBP (17.7 ± 5.9 mmHg; p < 0.001). Both diabetics and non-diabetics showed an identical pattern of significance with respect to the whole population. Systolic blood pressure, DBP, and microalbuminuria were significantly reduced as a consequence of therapy, both in diabetics and non-diabetics.

• hypertension
• diabetes mellitus
• telmisartan
• renoprotection
• albuminuria

ACKNOWLEDGMENTS

We would like to thank general physicians from our area of study for referring patients to be selected in this observational study and to the patients for their participation.

Declaration of interest: Jose C. Rodriguez-Perez was supported by a grant from Boehringer-Ingelheim for basic and clinical study.